Handelsbanken Fonder
TVRD

Handelsbanken Fonder’s Tvardi Therapeutics TVRD Stock Holding History

Handelsbanken Fonder’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-294
Closed -$97K – 1604
2022
Q2 		$97K Sell
294
-137
-32% -$48.1K ﹤0.01% 1582
2022
Q1 		$188K Hold
431
– – ﹤0.01% 1642
2021
Q4 		$189K Hold
431
– – ﹤0.01% 1715
2021
Q3 		$239K Hold
431
– – ﹤0.01% 1628
2021
Q2 		$221K Buy
+431
New +$273K ﹤0.01% 1687

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Handelsbanken Fonder's TVRD Position: Q3 2022 in Review

Handelsbanken Fonder sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 294 shares — an estimated $97K sold.

Handelsbanken Fonder first reported a position in TVRD in Q2 2021 and held it in 5 quarters. The position peaked at $239K in Q3 2021. 165 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

  • Handelsbanken Fonder reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 294 Tvardi Therapeutics shares in Q3 2022, an estimated $97K.
  • Handelsbanken Fonder first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 5 quarters.
  • Handelsbanken Fonder's Tvardi Therapeutics position peaked at $239K in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on Handelsbanken Fonder's 13F filing for Q3 2022, filed 27 Oct 2022.